Autopsy report · NCT02623595
A Study of SBRT in Combination With rhGM-CSF for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy
Cause of deathSlow enrollment
“Patient enrollment was hard mainly due to we need at least three lesions suitable for SBRT”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 2
- Sponsor
- Wuhan University
- Sponsor type
- University, hospital or other
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Stereotactic body radiotherapy; rhGM-CSF
- Participants
- 0
- Sites
- 1
- Countries
- China
Trials that died the same way
- Intra-erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-dependent Crohn's Disease
“due to the difficulty to enroll suitable patients” - Platelet Function With New Pediatric Oxygenator and Heparin and Non Heparin Coating in Pediatric Cardiac Surgery
“for difficulty to enroll patients in the study” - Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients
“Hard to enroll expected number of eligible patients.” - Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)
“difficulty of enrolling patients” - Safety, Tolerability, PK and PD of Intravenous Ferric Carboxymaltose in Infants With Iron Deficiency Anemia
“Difficult to recruit and enroll patients for this study in a reasonable amount of time.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.